上海谊众(688091) - 2024 Q4 - 年度业绩

Financial Performance - The total revenue for 2024 was RMB 173,825,025.22, a decrease of 51.75% compared to RMB 360,253,871.23 in the previous year[4] - The net profit attributable to the parent company was RMB 6,850,041.02, down 95.76% from RMB 161,553,919.38 in the same period last year[4] - The basic earnings per share decreased to RMB 0.03, a decline of 97.06% from RMB 1.02 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 1,448,233,847.64, a decrease of 7.95% from the beginning of the period[4] - The company's equity attributable to the parent company was RMB 1,404,895,559.27, down 4.09% from the beginning of the period[4] Product Performance and Strategy - The company’s core product, paclitaxel micelles, saw a significant decline in sales, impacting revenue and profit[7] - The company increased its investment in nationwide sales layout to promote the core product after it was included in the medical insurance directory, affecting profits[7] - The company has completed the network access in all provinces and municipalities, and the paclitaxel micelles have entered the dual-channel management directory in over 20 provinces[8] Capital and Financial Reporting - The company’s share capital increased by 30.52% due to the implementation of a capital reserve conversion plan and the completion of the first vesting period of the 2022 equity incentive plan[9] - The financial data presented are preliminary and subject to change upon the release of the audited annual report[10]